Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1278

1.

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.

de Vries Schultink AHM, Huitema ADR, Beijnen JH.

Breast. 2018 Aug 22;42:38-40. doi: 10.1016/j.breast.2018.08.100. [Epub ahead of print]

PMID:
30153552
2.

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.

Sparidans RW, Li W, Schinkel AH, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Aug 19;161:136-143. doi: 10.1016/j.jpba.2018.08.038. [Epub ahead of print]

PMID:
30149189
3.

Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Oncology in a Real-world Cohort Study: Does Age Matter?

Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Br J Clin Pharmacol. 2018 Aug 1. doi: 10.1111/bcp.13725. [Epub ahead of print]

PMID:
30068020
4.

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N, Rosing H, Beijnen JH, Huitema ADR, Guchelaar HJ, Cats A, Schellens JHM.

Br J Clin Pharmacol. 2018 Jul 26. doi: 10.1111/bcp.13719. [Epub ahead of print]

PMID:
30047584
5.

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

van Andel L, Rosing H, Schellens JH, Beijnen JH.

Mar Drugs. 2018 Jul 23;16(7). pii: E246. doi: 10.3390/md16070246. Review.

6.

Buparlisib is a brain penetrable pan-PI3K inhibitor.

de Gooijer MC, Zhang P, Buil LCM, Çitirikkaya CH, Thota N, Beijnen JH, van Tellingen O.

Sci Rep. 2018 Jul 17;8(1):10784. doi: 10.1038/s41598-018-29062-w.

7.

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.

van Nuland M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, Rosing H, Schellens JHM, Beijnen JH, Hövels AM.

Breast Cancer Res Treat. 2018 Jul 13. doi: 10.1007/s10549-018-4886-8. [Epub ahead of print]

PMID:
30006796
8.

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin.

van Andel L, Rosing H, Tibben MM, Lucas L, Lubomirov R, Avilés P, Francesch A, Fudio S, Gebretensae A, Hillebrand MJX, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Sep;82(3):441-455. doi: 10.1007/s00280-018-3637-1. Epub 2018 Jul 4.

PMID:
29974200
9.

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Kip AE, Wasunna M, Alves F, Schellens JHM, Beijnen JH, Musa AM, Khalil EAG, Dorlo TPC.

Front Cell Infect Microbiol. 2018 Jun 1;8:181. doi: 10.3389/fcimb.2018.00181. eCollection 2018.

10.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.

van Andel L, Rosing H, Lubomirov R, Avilés P, Fudio S, Tibben MM, Nan-Offeringa L, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Sep 5;158:160-165. doi: 10.1016/j.jpba.2018.05.053. Epub 2018 Jun 1.

PMID:
29883879
11.

Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology.

Groenland SL, van Nuland M, Verheijen RB, Schellens JHM, Beijnen JH, Huitema ADR, Steeghs N.

Clin Pharmacokinet. 2018 Jun 4. doi: 10.1007/s40262-018-0683-0. [Epub ahead of print] Review.

PMID:
29862467
12.

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.

de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O.

Neoplasia. 2018 Jul;20(7):710-720. doi: 10.1016/j.neo.2018.05.001. Epub 2018 May 28.

13.

Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.

Rood JJM, Dormans PJA, van Haren MJ, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:14-21. doi: 10.1016/j.jchromb.2018.05.011. Epub 2018 May 11.

14.

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Kip AE, Castro MDM, Gomez MA, Cossio A, Schellens JHM, Beijnen JH, Saravia NG, Dorlo TPC.

J Antimicrob Chemother. 2018 Aug 1;73(8):2104-2111. doi: 10.1093/jac/dky143.

PMID:
29757380
15.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J, Los-de Vries GT, Horlings H, Nuijen B, Beijnen JH, Schellens JHM, Bernards R.

Cell. 2018 May 31;173(6):1413-1425.e14. doi: 10.1016/j.cell.2018.04.012. Epub 2018 May 10.

PMID:
29754815
16.

P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.

Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH.

Int J Cancer. 2018 Oct 15;143(8):2029-2038. doi: 10.1002/ijc.31582. Epub 2018 Jul 10.

PMID:
29744867
17.

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.

de Vries Schultink AHM, Doornbos RP, Bakker ABH, Bol K, Throsby M, Geuijen C, Maussang D, Schellens JHM, Beijnen JH, Huitema ADR.

Invest New Drugs. 2018 May 5. doi: 10.1007/s10637-018-0593-x. [Epub ahead of print]

PMID:
29728897
18.

Solubility and bioavailability improvement of pazopanib hydrochloride.

Herbrink M, Groenland SL, Huitema ADR, Schellens JHM, Beijnen JH, Steeghs N, Nuijen B.

Int J Pharm. 2018 Jun 10;544(1):181-190. doi: 10.1016/j.ijpharm.2018.04.037. Epub 2018 Apr 19.

PMID:
29680279
19.

Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients.

Herbrink M, Nuijten M, Nuijen B, Huitema ADR, Beijnen JH, Hendriks VM, Blanken P, Janmohamed A, van den Brink W.

J Clin Psychopharmacol. 2018 Jun;38(3):212-217. doi: 10.1097/JCP.0000000000000862.

PMID:
29620701
20.

Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.

Spatari C, Li W, Schinkel AH, Ragno G, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:204-208. doi: 10.1016/j.jchromb.2018.03.014. Epub 2018 Mar 9.

21.

A multi-gram-scale stereoselective synthesis of Z-endoxifen.

Milroy LG, Koning B, Scheppingen DSV, Jager NGL, Beijnen JH, Koek J, Brunsveld L.

Bioorg Med Chem Lett. 2018 May 1;28(8):1352-1356. doi: 10.1016/j.bmcl.2018.03.008. Epub 2018 Mar 13.

22.

Palladium-induced granulomas analysed with inductively coupled plasma mass spectrometry.

Marsidi N, Beijnen JH, van Zuuren EJ.

Contact Dermatitis. 2018 Jul;79(1):41-42. doi: 10.1111/cod.12979. Epub 2018 Mar 1. No abstract available.

23.

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Derissen EJB, Huitema ADR, Rosing H, Schellens JHM, Beijnen JH.

Br J Clin Pharmacol. 2018 Jun;84(6):1279-1289. doi: 10.1111/bcp.13557. Epub 2018 Apr 16.

PMID:
29451684
24.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.

Jacobs BAW, Snoeren N, Samim M, Rosing H, de Vries N, Deenen MJ, Beijnen JH, Schellens JHM, Koopman M, van Hillegersberg R.

Eur J Clin Pharmacol. 2018 Jun;74(6):737-744. doi: 10.1007/s00228-018-2426-4. Epub 2018 Feb 11.

PMID:
29430582
25.

Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.

van Nuland M, Hillebrand MJX, Rosing H, Burgers JA, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Mar 20;151:25-31. doi: 10.1016/j.jpba.2017.12.048. Epub 2017 Dec 26.

PMID:
29294409
26.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N, Beijnen JH, Steeghs N, Huitema ADR.

Ther Drug Monit. 2018 Apr;40(2):230-236. doi: 10.1097/FTD.0000000000000479.

PMID:
29256969
27.

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry.

Burylo AM, de Weger VA, Stuurman FE, Beijnen JH, Schellens JHM.

Thromb Haemost. 2017 Dec;117(12):2356-2368. doi: 10.1160/TH17-04-0254. Epub 2017 Dec 6.

PMID:
29212123
28.

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

van Bussel MTJ, Pluim D, Bol M, Beijnen JH, Schellens JHM, Brandsma D.

J Neurooncol. 2018 Mar;137(1):1-10. doi: 10.1007/s11060-017-2691-6. Epub 2017 Nov 30. Review.

PMID:
29192390
29.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Jan;81(1):47. doi: 10.1007/s00280-017-3474-7.

30.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET.

Verheijen RB, Yaqub M, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, Steeghs N.

J Nucl Med. 2018 Jun;59(6):973-979. doi: 10.2967/jnumed.117.195800. Epub 2017 Nov 24.

PMID:
29175983
31.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, Beijnen JH.

Biomed Chromatogr. 2018 Apr;32(4). doi: 10.1002/bmc.4147. Epub 2017 Dec 19.

PMID:
29165815
32.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.

Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S, Beijnen JH, Schinkel AH.

Pharmacol Res. 2018 Mar;129:414-423. doi: 10.1016/j.phrs.2017.11.006. Epub 2017 Nov 14.

PMID:
29155017
33.

ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.

de Gooijer MC, Buil LCM, Beijnen JH, van Tellingen O.

Invest New Drugs. 2018 Jun;36(3):380-387. doi: 10.1007/s10637-017-0539-8. Epub 2017 Nov 17.

PMID:
29147815
34.

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM.

Clin Pharmacokinet. 2018 Apr;57(4):427-437. doi: 10.1007/s40262-017-0587-4. Review.

PMID:
29063517
35.

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.

Herbrink M, Thijssen B, Hillebrand MJX, Rosing H, Schellens JHM, Nuijen B, Beijnen JH.

J Pharm Biomed Anal. 2018 Jan 30;148:259-264. doi: 10.1016/j.jpba.2017.10.009. Epub 2017 Oct 18.

PMID:
29059615
36.

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.

van Nuland M, Rosing H, de Vries J, Ovaa H, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:119-124. doi: 10.1016/j.jchromb.2017.10.033. Epub 2017 Oct 16.

PMID:
29059586
37.

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

Verheijen RB, Swart LE, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1171-1178. doi: 10.1007/s00280-017-3463-x. Epub 2017 Oct 19.

38.

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.

Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM.

Ann Oncol. 2017 Dec 1;28(12):2915-2922. doi: 10.1093/annonc/mdx411.

PMID:
29045513
39.

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Jan;81(1):39-46. doi: 10.1007/s00280-017-3455-x. Epub 2017 Oct 17. Erratum in: Cancer Chemother Pharmacol. 2017 Nov 27;:.

40.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

de Weger VA, Stuurman FE, Hendrikx JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S.

Eur J Cancer. 2017 Nov;86:217-225. doi: 10.1016/j.ejca.2017.09.010. Epub 2017 Oct 12.

PMID:
29031170
41.

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.

de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB.

Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.

42.

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

Dorlo TPC, Kip AE, Younis BM, Ellis SJ, Alves F, Beijnen JH, Njenga S, Kirigi G, Hailu A, Olobo J, Musa AM, Balasegaram M, Wasunna M, Karlsson MO, Khalil EAG.

J Antimicrob Chemother. 2017 Nov 1;72(11):3131-3140. doi: 10.1093/jac/dkx283.

43.

The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.

de Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O.

Int J Cancer. 2018 Jan 15;142(2):381-391. doi: 10.1002/ijc.31052. Epub 2017 Oct 4.

PMID:
28921565
44.

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

van der Hiel B, Haanen JBAG, Stokkel MPM, Peeper DS, Jimenez CR, Beijnen JH, van de Wiel BA, Boellaard R, van den Eertwegh AJM; REPOSIT study group.

BMC Cancer. 2017 Sep 15;17(1):649. doi: 10.1186/s12885-017-3626-5.

45.

Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.

Janssen JM, Zwaan CM, Schellens JHM, Beijnen JH, Huitema ADR.

Eur J Cancer. 2017 Nov;85:78-85. doi: 10.1016/j.ejca.2017.07.050. Epub 2017 Sep 9.

PMID:
28892776
46.

Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).

Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Mol Pharm. 2017 Oct 2;14(10):3258-3268. doi: 10.1021/acs.molpharmaceut.7b00257. Epub 2017 Sep 19.

PMID:
28880088
47.

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction.

Retmana IA, Wang J, Schinkel AH, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:300-305. doi: 10.1016/j.jchromb.2017.07.034. Epub 2017 Jul 23.

48.

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial.

Verheijen RB, Atrafi F, Schellens JHM, Beijnen JH, Huitema ADR, Mathijssen RHJ, Steeghs N.

Clin Pharmacokinet. 2018 May;57(5):637-644. doi: 10.1007/s40262-017-0582-9.

49.

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Kip AE, Schellens JHM, Beijnen JH, Dorlo TPC.

Clin Pharmacokinet. 2018 Feb;57(2):151-176. doi: 10.1007/s40262-017-0570-0. Review.

50.

Fixed Dosing of Monoclonal Antibodies in Oncology.

Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH.

Oncologist. 2017 Oct;22(10):1212-1221. doi: 10.1634/theoncologist.2017-0167. Epub 2017 Jul 28. Review.

PMID:
28754722

Supplemental Content

Loading ...
Support Center